Skip to main content

Norway patent prosecution process.

The patent prosecution process in Norway is as follows:

1. **Filing:** 

Submit a patent application to the Norwegian Industrial Property Office (NIPO). The application can be a national application, a regional (European) application designating Norway, or an international (PCT) application entering the national phase.

2. **Formal Examination:** 

NIPO conducts a formal examination to ensure the application meets all requirements, such as correct documentation and fees.

3. **Substantive Examination:** 

If requested, NIPO conducts a substantive examination to assess the patentability criteria, including novelty, inventive step, and industrial applicability.

4. **Publication:** 

If the application meets the requirements, it is published 18 months from the filing date or priority date.

5. **Third-Party Observations:** 

Third parties can submit observations on the patentability of the application within a certain timeframe after publication.

6. **Grant or Refusal:** 

If the application is found to meet all criteria, a patent is granted. If not, the applicant may have the opportunity to respond to objections or amend the application.

7. **Validation:** 

For European patents, the granted European patent must be validated in Norway by submitting a translation of the claims into Norwegian and paying a fee.

8. **Maintenance:** 

Annual renewal fees must be paid to keep the patent in force.


It's important to note that patent prosecution procedures can change, and it's advisable to refer to the latest information from NIPO or consult legal experts for the most up-to-date guidance.


For more topics on patent prosecution ,litigation :

Click 👉 e-Pharmatimes



Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcur...

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing ...

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys...